Despite Inhibitory Effects on Normal Hematopoiesis in Vitro, Imatinib and Nilotinib do not Prevent Engraftment of Human CD34+ HSCs in immunodeficient NSG MiceBelle, Ludovic ; Baron, Frédéric ; Bruck, France et alPoster (2011) Detailed reference viewed: 1 (1 ULg) Rapamycin delays xenogeneic acute graft-versus-host disease (aGvHD) in NOD/SCID/IL2Rg NULL (NSG) mice: impact of regulatory T cells; BARON, Frédéric ; et alPoster (2011) Detailed reference viewed: 14 (7 ULg) The mTor inhibitor rapamycin delays xenogeneic acute graft versus host disease (aGVHD) in NOD/SCID/IL2rgnull mice (NSG): impact of regulatory T cells; BARON, Frédéric ; et alPoster (2011) Detailed reference viewed: 10 (3 ULg) Longitudinal Monitoring of Immune Reconstitution After Allogeneic Peripheral Blood Stem Cell Transplantation (HSCT): Impact of T Cell Depletion of the GraftSERVAIS, Sophie ; Hannon, Muriel ; Daulne, Coline et alin Belgian Journal of Hematology (2011), Abstracts book(Supplement of 26th General Meeting of the Belgian Hematological Society), 31 Detailed reference viewed: 1 (1 ULg) Thymic recovery after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning is limited to patients younger than 60 years of ageCASTERMANS, Emilie ; Hannon, Muriel ; et alin Haematologica (2011), 96(2) Detailed reference viewed: 22 (15 ULg) Effects of granulocyte-colony-stimulating factor on progenitor cell mobilization and heart perfusion and function in normal miceDELGAUDINE, Marie ; ; Lancellotti, Patrizio et alin Cytotherapy (2011), 13 Detailed reference viewed: 17 (8 ULg) Too low iron doses and too many dropouts in negative iron trial; Beguin, Yves ; et alin Journal of Clinical Oncology (2011) Detailed reference viewed: 3 (0 ULg) Lymphome du manteau : prise en charge 2011Bonnet, Christophe ; CAERS, Jo ; DE PRIJCK, Bernard et alin Revue Médicale Suisse (2011), 7 Le lymphome du manteau (LM) représente 6% des lymphomes non hodgkiniens (LNH). Le diagnostic repose sur l'immunophénotypage et la démonstration de la présence de la location entre les chromosomes 11 et 14 ... [more ▼] Le lymphome du manteau (LM) représente 6% des lymphomes non hodgkiniens (LNH). Le diagnostic repose sur l'immunophénotypage et la démonstration de la présence de la location entre les chromosomes 11 et 14, avec surexpression de la cycline D1. Le traitement de première ligne du sujet jeune associe trois cures de R-CHOP21 alternées avec trois cures de R-DHAP21, suivies d'une autogreffe conditionnée par irradiation corporelle totale, cyclophosphamide et aracytine. Le sujet de plus de 65 ans peut bénéficier de huit cures de R-CHOP21. L'intérêt du traitement de maintenance est en cours d'évaluation. L'allogreffe de cellules souches hématopoïétiques offre une chance de guérison aux patients en rechute en bon état général. Les traitements ciblés permettront une amélioration du pronostic de cette maladie. [less ▲] Detailed reference viewed: 42 (4 ULg) Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation (HSCT)Servais, Sophie ; Beguin, Yves ; Baron, Frédéric ![]() in Belgian Journal of Hematology (2011), 2 Reduced intensity conditioning (RIC) regimens have allowed performing allogeneic haematopoietic stem cell transplantation (HSCT) in patients for whom conventional myeloablative allogeneic HSCT is ... [more ▼] Reduced intensity conditioning (RIC) regimens have allowed performing allogeneic haematopoietic stem cell transplantation (HSCT) in patients for whom conventional myeloablative allogeneic HSCT is associated with unacceptable risks of non-relapse-mortality. This approac relies mainly on graft-versus-tumour effects for tumour eradication. Retrospective studies have suggested that, in patients aged 40 to 60 years, RIC-HSCT was associated with a higher risk of relapse but a lower incidence of transplant-related mortality than myeloablative allogeneic HSCT, leading to similar progression-free and overall survivals. After reviewing the rationale for RIC-HSCT, this article discusses the results of RIC-HSCT in specific deseases, and proposes what could be current indications for RIC-HSCT in 2011. Finally, the article briefly presents some possible strategies aimed at increasing the anti-tumoral activity of the procedure while reducing the incidence and severity of acute graft-versus-host disease. [less ▲] Detailed reference viewed: 52 (16 ULg) Allogeneic hematopoietic stem cell transplantation (HSCT) after reduced intensity conditioningSERVAIS, Sophie ; Baron, Frédéric ; Beguin, Yves ![]() in Transfusion & Apheresis Science (2011), 44 Allogeneic hematopoietic stem cell transplantation (HSCT) following myeloablative (conventional) conditioning regimen is associated with a high incidence of transplant-related morbidity and mortality ... [more ▼] Allogeneic hematopoietic stem cell transplantation (HSCT) following myeloablative (conventional) conditioning regimen is associated with a high incidence of transplant-related morbidity and mortality, limiting its use to younger patients without medical co-morbidities. Over the past few years, it has become more evident that the alloreactivty of transplanted donor immunocompetent cells against host tumor cells (graft-versus-tumor effects, GVT effects) plays a major role in eradicating malignancies after allogeneic HSCT. Based on these observations, several groups of investigators have developed reduced intensity conditioning (RIC) regimens allowing patients who are ineligible for conventional HSCT to benefit from the potentially curative GVT effects of allogeneic transplantation. Retrospective studies have suggested that, in comparison with myeloablative allogeneic HSCT, in patient aged 40-60 years, RIC HSCT was associated with a higher risk of relapse but a lower incidence of transplant-related mortality leading to similar progression-gree and overall survivals. Prospective studies are ongoing to define which patients might most benefit from RIC HSCT, and to increase the anti-tumoral activity of the procedure while reducing the incidence and the severity of acute graft-versus-host disease (GVHD). In this article, we review the current status and perspectives of RIC HSCT. [less ▲] Detailed reference viewed: 16 (2 ULg) Biological aspects of angiogenesis in multiple myeloma.Otjacques, Eléonore ; Binsfeld, Marilène ; Noël, Agnès et alin International Journal of Hematology (2011), 94(6), 505-18 Multiple myeloma (MM) is a hematological malignancy characterized by the aberrant expansion of malignant plasma cells within the bone marrow (BM). One of the hallmarks of this disease is the close ... [more ▼] Multiple myeloma (MM) is a hematological malignancy characterized by the aberrant expansion of malignant plasma cells within the bone marrow (BM). One of the hallmarks of this disease is the close interaction between myeloma cells and neighboring cells within the BM. Angiogenesis, through the activation of endothelial cells, plays an essential role in MM biology. In the current review, we describe the angiogenesis process in MM by identifying the interacting cells, the pro- and anti-angiogenic cytokines modulated, and the extracellular matrix degrading proteases liable to participate in the pathophysiology. Finally, we highlight the impact of hypoxia (through hypoxia-inducible factor-1) and constitutive activation of nuclear factor-κB in this tumor-induced neo-vascularization. [less ▲] Detailed reference viewed: 20 (3 ULg) Prise en charge actuelle des syndromes myélodysplasiquesCAERS, Jo ; BONNET, Christophe ; et alin Revue Médicale Suisse (2011), 7 Detailed reference viewed: 12 (6 ULg) Unrelated cord blood transplantation in adults with myelodysplasia or secondary acute myeloblastic leukemia : a survey on behalf of Eurocord and CLWP of EBMT; ; et al in Leukemia : Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K (2011), 25 Detailed reference viewed: 11 (3 ULg) Expression of components of the growth hormone (GH)/insulin-like growth factor (IGF) axis during Balb/c mouse thymus ontogeny and effects of GH upon ex-vivo T-cell differentiation; Goffinet, Lindsay ; Mottet, Marie et alPoster (2010, September) Detailed reference viewed: 44 (16 ULg) Thymic Recovery after Allogeneic Hematopoietic Cell Transplantation with non-Myeloablative Conditioning might Be Limited to Patients Younger than 60 Years of AgeHannon, Muriel ; ; et alConference (2010) Detailed reference viewed: 2 (2 ULg) Elevations of tumor necrosis factor-receptor-1 at day 7 and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioningWillems, Evelyne ; Humblet-Baron, Stéphanie ; Dengis, Olivier et alin Bone Marrow Transplantation (2010), 45 Detailed reference viewed: 6 (1 ULg) Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning.Baron, Frédéric ; Lechanteur, Chantal ; Willems, Evelyne et alin Biology of Blood & Marrow Transplantation (2010), 16(6), 838-47 Recent studies have suggested that coinfusion of mesenchymal stem cells (MSCs) the day of hematopoietic cell transplantation (HCT) might promote engraftment and prevent graft-versus-host disease (GVHD ... [more ▼] Recent studies have suggested that coinfusion of mesenchymal stem cells (MSCs) the day of hematopoietic cell transplantation (HCT) might promote engraftment and prevent graft-versus-host disease (GVHD) after myeloablative allogeneic HCT. This prompted us to investigate in a pilot study whether MSC infusion before HCT could allow nonmyeloablative (NMA) HCT (a transplant strategy based nearly exclusively on graft-versus-tumor effects for tumor eradication) from HLA-mismatched donors to be performed safely. Twenty patients with hematologic malignancies were given MSCs from third party unrelated donors 30-120 minutes before peripheral blood stem cells (PBSCs) from HLA-mismatched unrelated donors, after conditioning with 2 Gy total body irradiation (TBI) and fludarabine. The primary endpoint was safety, defined as a 100-day incidence of nonrelapse mortality (NRM) <35%. One patient had primary graft rejection, whereas the remaining 19 patients had sustained engraftment. The 100-day cumulative incidence of grade II-IV acute GVHD (aGVHD) was 35%, whereas 65% of the patients experienced moderate/severe chronic GVHD (cGVHD). One-year NRM (10%), relapse (30%), overall survival (OS) (80%) and progression-free survival (PFS) (60%), and 1-year incidence of death from GVHD or infection with GVHD (10%) were encouraging. These figures compare favorably with those observed in a historic group of 16 patients given HLA-mismatched PBSCs (but no MSCs) after NMA conditioning, which had a 1-year incidence of NRM of 37% (P = .02), a 1-year incidence of relapse of 25% (NS), a 1-year OS and PFS of 44% (P = .02), and 38% (P = .1), respectively, and a 1-year rate of death from GVHD or infection with GVHD of 31% (P = .04). In conclusion, our data suggest that HLA-mismatched NMA HCT with MSC coinfusion appeared to be safe. [less ▲] Detailed reference viewed: 49 (25 ULg) GVHD chronique et effet anti-tumoralBaron, Frédéric ; Beguin, Yves ![]() in Correspondance en Onco-Hématologie (2010), 5 It was demonstrated in 1981 that chronic GVHD was associated with a strong decrease of the relapse risk after conventional allogeneic hematopoietic cell transplantation (graf-versus-tumor effects). Recent ... [more ▼] It was demonstrated in 1981 that chronic GVHD was associated with a strong decrease of the relapse risk after conventional allogeneic hematopoietic cell transplantation (graf-versus-tumor effects). Recent studies suggest that chronic GVHD might also been associated with improved progression-gree survival after allogeneic hematopoietic cell transplantation with reduced-intensity conditioning (RIC-allo), a transplant strategy based mainly on graft-versus-tumor effects for tumor eradication. Further, it has been demonstrated that elimination of leukemic cells after RIC-allo is due to donor T-cell cloones directed against multiple minor histocompatibility antigens (specific for the recipient) that are largely expressed not only by tumor cells but also by non-hematopoietic tissues, explaining the strong association between GVHD and graft-versus-tumor effects seen after RIC-allo. [less ▲] Detailed reference viewed: 28 (0 ULg) Comparison of thrombotic microangiopathy after allogeneic hematopoietic cell transplantation with high-dose or nonmyeloablative conditioningWillems, Evelyne ; Baron, Frédéric ; Seidel, Laurence et alin Bone Marrow Transplantation (2010), 45 Detailed reference viewed: 7 (4 ULg) Prolonged ex vivo culture of human bone marrow mesenchymal stem cells influences their supportive activity toward NOD/SCID -repopulating cells and committed progenitor cells of B lymphoid and myeloid lineagesBriquet, Alexandra ; Dubois, Sophie ; Bekaert, Sandrine et alin Haematologica (2010), 95(1), 47-56 Background Bone marrow (BM) mesenchymal stem cells (MSC) support proliferation and differentiation of hematopoietic progenitor cells (HPC) in vitro. Since they represent a rare subset of BM cells, MSC ... [more ▼] Background Bone marrow (BM) mesenchymal stem cells (MSC) support proliferation and differentiation of hematopoietic progenitor cells (HPC) in vitro. Since they represent a rare subset of BM cells, MSC preparations for clinical purposes involves a preparative step of ex vivo multiplication. The aim of our study was to analyze the influence of culture duration on MSC supportive activity. DESIGN AND METHODS: MSC were expanded for up to 10 passages. MSC and CD34(+) cells were seeded in cytokine-free co-cultures after which the phenotype, clonogenic capacity and in vivo repopulating activity of harvested hematopoietic cells were assessed. RESULTS: Early passage MSC supported HPC expansion and differentiation toward both B lymphoid and myeloid lineages. Late passage MSC did not support HPC and myeloid cell outgrowth but maintained B cell supportive ability. In vitro maintenance of NOD/SCID mouse repopulating cells cultured for one week in contact with MSC was effective until the fourth MSC passage and declined afterwards. CD34(+) cells achieved higher levels of engraftment in NOD/SCID mice when co-injected with early passage MSC; however MSC expanded beyond 9 passages were ineffective in promoting CD34(+) cell engraftment. Non-contact cultures indicated that MSC supportive activity involved diffusible factors. Among these, interleukin (IL)-6 and IL-8 contributed to the supportive activity of early passage MSC but not of late passage MSC. MSC phenotype as well as fat, bone and cartilage differentiation capacity did not change during MSC culture. Conclusions Extended MSC culture alters their supportive ability toward HPC without concomitant changes in phenotype and differentiation capacity. [less ▲] Detailed reference viewed: 77 (40 ULg) |
||